Tag Archives: Emerging Companies

Drug Discovery & Development: Partnering for Success…and Survival

There are pressures on Big Pharma and biotech emerging companies alike to engage in more creative deal making to ensure positive outcomes for both parties, Ted Agres writes in Drug Discovery and Development. While the number of deals has remained relatively flat in 2011, the dollar amount of individual deals has increased overall. Oncology remains the most sought after category, followed by CNS, anti-infectives, metabolic diseases, dermatology and cardiovascular. Partnering activity at BIO events is on Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

The Critical Importance of International Patent Protection for Small Businesses

Stanley Erck

As part of the implementation of the Leahy-Smith America Invents Act, the U.S. Patent and Trademark Office (PTO) recently held two public hearing on international patent protection.  Stanley C. Erck, President and CEO of Novavax, Inc., testified on behalf of BIO in support of an initiative to reduce filing and prosecution costs for international patent protection of biotech inventions. In his testimony, Mr. Erck explained the important role patents play in the biotechnology industry. The Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

State Deficits to Shrink & Taxes Drop – Good News for Biotech

Michigan State Capitol dome interior, Lansing, MI

Forecasters at the National Conference of State Legislatures’ 2011 Legislative Summit expect a dramatic reduction of state deficits in the coming years, along with business-friendly tax-cuts. The projections are based on a survey of budget officials in all 50 states last month, said Corina Eckl, director of state services for NCSL. Eckl also noted an emerging trend in which state governors and legislatures are allowing for the expiration of temporary business taxes. Notably, the Michigan Business Read More >

Business of Biotech  |  1 Comment  |  Email This Post
Tags: , , , , , ,

Raising the Stakes in Biotech

JimGreenwood

Small biotech companies continue to struggle to obtain funding as capital markets remain tight. The S&P downgrade may create even tighter credit markets and raise the cost of available credit, for small and large companies. To the extent that the downgrade leads capital flows out of the U.S., that hurts biotech. Biotech’s contributions to the world are critically needed. Our industry holds great promise for curing and treating many prevalent diseases, such as Alzheimer’s, cancer, Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,